Article
Immunology
Priyanka Devi-Marulkar, Carolina Moraes-Cabe, Pascal Campagne, Beatrice Corre, Aida Meghraoui-Kheddar, Vincent Bondet, Alba Llibre, Darragh Duffy, Elisabeth Maillart, Caroline Papeix, Sandra Pellegrini, Frederique Michel
Summary: This study investigated the blood signatures associated with the efficacy of IFN beta treatment in RRMS patients. Non-responders showed specific changes in immune cells and approximately 600 immune-related genes, as well as specific HLA-DQB1 genotypes, suggesting potential resistance to therapeutic IFN beta.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Shahram Seyfi, Kayvan Latifi, Parviz Amri Male, Mahmoud Sadeghi Haddad Zavareh, Khadijeh Ezoji, Mousa Mohammadnia-Afrozi
Summary: This study retrospectively evaluated the clinical treatment outcomes of COVID-19 inpatients who received IFN-beta 1-a and IFN-beta 1-b. The results showed no significant difference between the two groups in terms of shortening disease time, clinical improvements, and other outcomes.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Francesco Piras, Lilian Arnaud, Eric Henninger, Matthew Keiser, Andrea Seitzinger, Dominic Jack, Quentin Le Masne
Summary: This study investigated adherence to, and duration of persistence with, the newest version of the RebiSmart (R) autoinjector among people with multiple sclerosis. The results showed that patients were highly adherent to using the device, and the longest persistence was observed in older individuals and males.
EXPERT OPINION ON DRUG DELIVERY
(2023)
Article
Biochemistry & Molecular Biology
M. Jacobs, M. Geiger, S. Summers, T. Janes, R. Boyea, K. Zinn, R. Aburashed, D. Spence
Summary: Multiple sclerosis (MS) is an inflammatory disease characterized by damage to the myelin sheath. Interferon-beta (IFN-β) has been found to reduce the hypermetabolic state and improve red blood cell function in MS patients.
ACS CHEMICAL NEUROSCIENCE
(2022)
Article
Immunology
Pablo Aliaga-Gaspar, Isaac Hurtado-Guerrero, Nicolas Lundahl Ciano-Petersen, Patricia Urbaneja, Isabel Brichette-Mieg, Virginia Reyes, Jose Luis Rodriguez-Bada, Roberto Alvarez-Lafuente, Rafael Arroyo, Ester Quintana, Lluis Ramio-Torrenta, Ana Alonso, Laura Leyva, Oscar Fernandez, Begona Oliver-Martos
Summary: IFN-beta treatment induces sIFNAR2 production in RRMS, with higher levels associated with a reduction in therapeutic response. In the short-term, some patients showed increased sIFNAR2 expression after IFN-beta stimulation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Ricardo Alonso, Juan Rojas, Juan Ramos, Patricio Correa, Cecilia Pita, Leila Cohen, Sandra Vanotti, Orlando Garcea, Berenice A. Silva
Summary: This study evaluates the adherence to disease-modifying drugs in multiple sclerosis patients in Argentina and Ecuador. The overall adherence rate was 78.1%, with no significant difference between the two countries. Factors such as infusion therapy, shared decision-making, lower EDSS scores, and shorter treatment durations were identified as predictors of adherence.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Arthur Allignol, Emmanuelle Boutmy, Meritxell Sabido Espin, Kurt Marhardt, Patrick Vermersch
Summary: In this real-world setting, the effectiveness of sc IFN beta-1a does not appear to be reduced based on age. Older patients showed lower discontinuation rates and reduced disease activity, as evidenced by lower relapse rates and fewer MRI scans compared to younger patients.
FRONTIERS IN NEUROLOGY
(2021)
Article
Medicine, General & Internal
Zbysek Pavelek, Michal Novotny, Blanka Klimova, Marek Peterka, Pavel Potuznik, Martina Kovari, Martin Valis
Summary: The study demonstrates high satisfaction among patients with the overall convenience and ease of use of RebiSmart 2.0. Over 80% of patients rated the device as very easy or easy to use in various domains, and all patients would recommend it to others in need of Rebif therapy.
CURRENT MEDICAL RESEARCH AND OPINION
(2021)
Article
Clinical Neurology
Giovanna Borriello, Carlo Pozzilli
Summary: The data suggest that early initiation of disease-modifying therapy is essential for patients with pediatric-onset multiple sclerosis (POMS) to slow progression. Two cases presented in the study demonstrated sustained clinical benefit from treatment with fingolimod for more than 2 years, indicating its safety and effectiveness as first- or second-line therapy in children with POMS.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Wolfgang Koehler, Kirsten Bayer-Gersmann, Thomas Neusser, Markus Schuerks, Tjalf Ziemssen
Summary: The study found high compliance with IFN beta-1b treatment in patients with multiple sclerosis in Germany using the BETACONNECT autoinjector, but persistence and adherence decreased over time. Factors influencing medication-taking behavior included intake of vitamin D supplements, absence of specific injection site reactions, age, treatment history, and patient experience with IFN beta-1b. Satisfaction with the autoinjector was high throughout the study period.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Karina Bustos, Javier Navarra, Melisa Godoy, Mariana Gonzalez
Summary: The study found that certain personality traits are associated with adherence to pharmacological and neurorehabilitation treatments in patients with MS. Understanding these traits can help develop individualized strategies to improve treatment adherence.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Review
Clinical Neurology
Isabel Sanchez-Vera, Esther Escudero, Ursula Munoz, Maria C. Sadaba
Summary: Multiple sclerosis (MS) is a debilitating disease that affects the central nervous system, often leading to the need for wheelchair assistance within 15 years of onset. Currently, there is no standardized technique for diagnosing MS, with the detection of oligoclonal IgG bands (OIgGBs) being the most sensitive assay, but limited to reference laboratories and requiring cerebrospinal fluid. Early diagnosis is crucial for better disease management, but existing disease modifying therapies come with significant side effects and a considerable percentage of patients discontinuing treatment. Research has focused on identifying predictive biomarkers for treatment response, and a new assay involving the detection of serum IgM to phosphatidylcholine has shown promise in predicting treatment response.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Chemistry, Multidisciplinary
Luis F. Gonzalez, Eric Acuna, Gabriel Arellano, Paola Morales, Paula Sotomayor, Felipe Oyarzun-Ampuero, Rodrigo Naves
Summary: A new delivery system of IFN-β nanoparticles via intranasal administration was developed to improve clinical symptoms and control neuroinflammation in an experimental model of multiple sclerosis, showing potential effectiveness, non-invasiveness, and cost-effectiveness as a therapy for MS.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Immunology
Ide Smets, Teresa Prezzemolo, Maya Imbrechts, Klara Mallants, Tania Mitera, Stephanie Humblet-Baron, Benedicte Dubois, Patrick Matthys, Adrian Liston, An Goris
Summary: The study indicates that both fingolimod and interferon-beta induce BAFF protein and mRNA expression, leading to a shift in the B cell pool towards a regulatory phenotype. Specifically, BAFF protein correlated with an increase in transitional B cells, decrease in switched B cells, and reduction in B cell-surface BAFF-R expression. However, BAFF does not directly influence the expression of immunoregulatory cytokines IL-10 and IL-35.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Livia Pena Silveira, Cristiane Aparecida Menezes de Padua, Paula Lana de Miranda Drummond, Jessica Soares Malta, Roberta Marcia Marques dos Santos, Naiane Lima Costa, Taisa Roberta Lopes Machado, Adriano Max Moreira Reis
Summary: This study aimed to validate the Treatment Adherence Measure (TAM) instrument in outpatient MM patients, but the results showed limitations in measuring patient adherence, with a high proportion of patients showing high adherence.
FRONTIERS IN PHARMACOLOGY
(2021)